Document Detail


Everolimus causing severe hypertriglyceridemia and acute pancreatitis.
MedLine Citation:
PMID:  23307976     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Everolimus is an mTOR inhibitor commonly used to treat metastatic pancreatic neuroendocrine tumors (pNETs) and renal cell carcinoma, and for posttransplant immunosuppression. This report presents a case of a 36-year-old man being treated with everolimus for a metastatic pNET who developed severe hypertriglyceridemia and acute pancreatitis. The incidence of hypertriglyceridemia reported in large prospective randomized trials is reviewed and the management of hypertriglyceridemic pancreatitis is discussed. Careful monitoring of triglyceride levels and dose adjustments of everolimus together with lipid-lowering therapy can allow patients to continue this medication. Because there are increasing indications for the use of everolimus, prescribing oncologists must be cognizant of the common and serious side effects.
Authors:
Somasundaram Subramaniam; Jason A Zell; Pamela L Kunz
Related Documents :
7734906 - Scoring approaches to the recognition of cases of sudden infant death syndrome.
12100446 - Neonatal tetanus elimination in mpumalanga province, south africa.
16517926 - Fatal case of community-acquired bacteremia and necrotizing fasciitis caused by chryseo...
23886726 - Modified serial extraction in a case with missing mandibular second premolars and a bri...
10746986 - Coexistence of myelodysplastic syndrome and multiple myeloma.
16940936 - Knee osteonecrosis due to lead poisoning: case report and review of the literature.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of the National Comprehensive Cancer Network : JNCCN     Volume:  11     ISSN:  1540-1413     ISO Abbreviation:  J Natl Compr Canc Netw     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-11     Completed Date:  2013-07-08     Revised Date:  2013-11-05    
Medline Journal Info:
Nlm Unique ID:  101162515     Medline TA:  J Natl Compr Canc Netw     Country:  United States    
Other Details:
Languages:  eng     Pagination:  5-9     Citation Subset:  IM    
Affiliation:
Stanford Cancer Institute, Stanford, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antineoplastic Agents / adverse effects*
Humans
Hypertriglyceridemia / chemically induced*
Male
Neuroendocrine Tumors / drug therapy*
Pancreatic Neoplasms / drug therapy*
Pancreatitis / chemically induced*
Sirolimus / adverse effects,  analogs & derivatives*
Grant Support
ID/Acronym/Agency:
P30 CA062203/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 159351-69-6/everolimus; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A new tonometer--the Corvis ST tonometer: clinical comparison with noncontact and Goldmann applanati...
Next Document:  Multiple Myeloma, Version 1.2013.